| Summary: | Ixekizumab is a humanized monoclonal antibody that selectively inhibits interleukin 17A, a pro-inflammatory cytokine implicated in the pathogenesis of a variety of autoimmune diseases, including plaque psoriasis. Ixekizumab has a Health Canada indication for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The manufacturer has requested that ixekizumab be evaluated for reimbursement per the Health Canada indication. The objective of this report was to perform a systematic review of the beneficial and harmful effects of ixekizumab administered by subcutaneous injection for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy
|
|---|